ClinicalTrials.gg
CompletedNCT05536661HYAGAMEUpdated Sep 13, 2022

Impact of Tear Substitute Use on Dry Eye in Gamers.

An interventional study of Preservative free hyaluronic acid artificial tear in Evaporative Dry Eye, sponsored by Laboratorios Thea, Spain. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Laboratorios Thea, Spain · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Jul 2019, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Enrollment
22nd of 41
56 · median 60
Started
2019
with 6 others
No phase
21 of 44
1 open now
Registered
27th of 44
by date
Lead sponsor
2 of 44
Laboratorios Thea, Spain

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 22nd largest by enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2019, is one of 21 with no phase, and was the 27th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

Clinical, prospective, comparative, controlled, single-blind study, on the signs and symptoms of dry eye before and after 3 days of playing video games with the use of artificial tears (Hyabak) versus no intervention.

Read the detailed description

Adult attendees to a Gamers convention will complete questionnairs and undergo an opthalmological evaluation before and after playing for 3 days in a row. Participants will be randomized into 2 groups of equal size:

  1. Study group.
  2. Control group. The Study group will instill hyaluronic acid 0.15% artificial tears in both eyes 4 times a day during the 3 days of the video game session, while the control group will not instill artificial tears.
03

Conditions studied

  • Evaporative Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Participants in videogame convention planning to play video games for a minimum of 6 hours daily for the next 3 days.
  • Voluntarily accept to participate and sign form

Exclusion criteria

Exclusion Criteria:

  • Ocular, nasolagrimal or palpebral active condition different from dry eye disease.
  • History of ocular trauma or infecction in the last 3 months previous to inclusion.
  • History of refractive surgery.
  • Visual acuity 0.5 or less in at least 1 eye.
  • Ocular medication use in the 3 days prior to inclusion.
  • History of systemic condition asociated to dry eye.
  • Use of systemic medication known to induce dry eye in the last 30 days.
  • Known allergy to hyaluronic acid.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Study group

    Preservative free Hyaluronic acid 0.15% artificial tear instilled in both eyes 4 times daily for 3 days

    Other: Preservative free hyaluronic acid artificial tear

  • No intervention
    Control group

    No artificial tear instilation

Interventions

  • OtherPreservative free hyaluronic acid artificial tear

    Ocular lubricant

06

What researchers measure

Primary outcomes

  1. Standard Patient Evaluation of Eye Dryness (SPEED)

    Change in Standard Patient Evaluation of Eye Dryness (SPEED) score between study and control group (range 0-28, with higher scores indicative of dry eye disease symptoms)

    Time frame: Between Day 1 and Day 3

Secondary outcomes

  1. Conjunctival hyperemia measured with McMonnies Chapman scale

    Change in McMonnies Chapman score (range 0-5, with higher scores indicative of more conjunctival hyperemia) between study and control group

    Time frame: Between Day 1 and Day 3

  2. Tear Breakup Time (TBUT)

    Change in Tear Breakup Time (TBUT) score (normal values \> or equal to 10 seconds) between study and control group

    Time frame: Between Day 1 and Day 3

  3. Conjunctival staining with lisamine green measured with Oxford scale

    Change in conjunctival oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group

    Time frame: Between Day 1 and Day 3

  4. Corneal staining with fluorescein measured with Oxford scale

    Change in corneal oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group

    Time frame: Between Day 1 and Day 3

  5. Schirmer I tear volume test

    Change in Schirmer score (normal values equal or higher than 10) between study and control group

    Time frame: Between Day 1 and Day 3

  6. Near convergence measured with a RAF binocular gauge

    Change in near convergence between study and control group

    Time frame: Between Day 1 and Day 3

  7. Accomodation distance measured with a RAF binocular gauge

    Change in accomodation distance between study and control group

    Time frame: Between Day 1 and Day 3

07

Study locations

1 site
  • Dreamhack Convention
    Valencia, 46035, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jul 2019, 0 months.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 0 months is below that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 13, 2022
StartActual
Jul 4, 2019
Primary completionActual
Jul 7, 2019
CompletionActual
Jul 7, 2019
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05536661
Lead sponsor
Laboratorios Thea, Spain
Collaborators
Crossdata
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Jul 4, 2019
Primary completion
Jul 7, 2019
Completion
Jul 7, 2019
Last update
Sep 13, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion